- Core One Labs’ (COOL) subsidiary Vocan Biotechnologies has initiated the engineering and design of a proprietary production system for the manufacturing of API-Grade DMT
- DMT is currently under clinical investigation for the treatment of certain mood disorders
- The research team plans to construct a high-throughput production system based on the same recombinant enzyme fermentation platform Core One is already developing for API-psilocybin
- The team intends to accelerate the development stage of its DMT production within a few weeks to track the first DMT provisional patent filling
- Core One Labs Inc. (COOL) is down 2.04 per cent and is trading at C$0.96 at market close
Core One Labs’ (COOL) subsidiary Vocan Biotechnologies has initiated the engineering and design of a production system to manufacture API-Grade N,N-dimethyltryptamine (DMT).
DMT, a naturally occurring psychedelic substance, is currently under clinical investigation for the treatment of certain mood disorders.
The compound is a primary component of traditional South American entheogenic brews and is traditionally derived from the leaves of a variety of plants endemic to equatorial regions across the globe.
The Vocan team has outlined a genetic pathway that could result in potentially elevated levels of DMT biosynthesis compared to the naturally occurring production pathway in the plants from which the compound is commonly extracted.
With further development the research team plans to construct a high-throughput production system based on the same recombinant enzyme fermentation platform Core One is already developing for API-psilocybin.
The addition of this biosynthetic target to its development pipeline will allow Vocan to broaden its offerings of clinical-quality psychedelic medicines and enable advancement of the therapeutic use of psychedelic substances in medicine.
This proprietary approach to DMT production will preserve the highly specific molecular structure of naturally occurring plant-derived DMT and allow the Company’s fermentative biosynthesis platform to be optimized for maximum DMT output at production scale.
The team intends to accelerate the current development stage of its DMT production system within a few weeks in order to fast-track the first DMT provisional patent filling with the US Patent and Trademark Office.
Early patent protection of its proprietary DNA sequences and enhanced-activity enzymes will ensure API-grade DMT can be manufactured by a repeatable and reliable process without any requirement for more costly chemical synthesis or cultivation, extraction, and purification from plant sources.
“Core One’s research and development division, through the leadership of Dr. Robert Hancock, continues to achieve significant scientific milestones in the production of biosynthesized and stereochemically sound psychedelic compounds, “stated Joel Shacker CEO of Core One Labs.
“We will continue to develop and expand our psychedelic product offerings, to provide the scientific research community with the compounds they need, and the successful engineering of enzymatic DMT is another example of how we can do this,”added Shacker.
Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy.
Core One Labs Inc. (COOL) is down 2.04 per cent and is trading at C$0.96 at market close.
